Geron Corporation Announces Executive Leadership Transitions and Appointments
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: GlobeNewswire
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company’s leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commercial Officer, will also depart on October 15, 2025, to pursue other interests. Succeeding Jim, Ahmed ElNawawi (“Nawawi”) has been appointed Executive Vice President, Chief Commercial Officer, effective October 20, 2025. In this role, Nawawi will assume leadership of Geron’s commercial organization
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsPR Newswire
- Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]Yahoo! Finance
- Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help [Seeking Alpha]Seeking Alpha
- Geron (NASDAQ:GERN) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire
GERN
Earnings
- 11/5/25 - In-Line
GERN
Sec Filings
- 11/7/25 - Form 10-Q
- 11/5/25 - Form 8-K
- 10/20/25 - Form 3
- GERN's page on the SEC website